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Objective. To review the literature on fat modifying dietary supplements commonly used for weight loss. Methods.R e c e n t l y
published randomized, placebo-controlled trials were identiﬁed in PubMed, MEDLINE, International Pharmaceutical Abstracts,
Cochrane Database, and Google Scholar using the search terms dietary supplement, herbal, weight loss, obesity, and individual
supplementnames.Discussion.Dataforconjugatedlinoleicacid(CLA),Garciniacambogia,chitosan,pyruvate,Irvingiagabonensis,
and chia seed for weight loss were identiﬁed. CLA, chitosan, pyruvate, and Irvingia gabonensis appeared to be eﬀective in weight
loss via fat modifying mechanisms. However, the data on the use of these products is limited. Conclusion. Many obese people use
dietarysupplementsforweightloss.Todate,thereislittleclinicalevidencetosupporttheiruse.Moredataisnecessarytodetermine
theeﬃcacyandsafetyofthesesupplements.Healthcareprovidersshouldassistpatientsinweighingtherisksandbeneﬁtsofdietary
supplement use for weight loss.
1.Introduction
The prevalence of obesity has continued to increase over the
lastseveralyearsintheUnitedStates.PertheNationalHealth
and Nutrition Examination Survey (NHANES) for the 2007-
2008 year, the prevalence of obesity, deﬁned as a body mass
index(BMI) ≥30kg/m2,amongadultswasgreaterthan30%
and those who were overweight or obese (BMI ≥ 25kg/m2)
was almost 70% for both men and women. The trend over
the past 20 years has shown an increase in the prevalence of
obesity of six to seven percent every 10 years [1]. In addition,
health care costs are approximately 42% higher for obese
patients when compared to normal-weight patients [2].
Dietary supplements for weight loss are marketed to
oﬀer patients improved success that is faster and easier than
calorie reduction and increased exercise. Despite concerns
with eﬃcacy and safety, these products continue to be an
appealing alternative or adjunct to weight management [3,
4]. A national survey published in 2008 found that 33.9%
of adults who have made a weight loss attempt had used
a dietary supplement to do so. It was also found that the
use was more common among women, younger adults,
minorities, and those with less education and lower incomes
[5]. Reasons why patients may opt for dietary supplements
include the perception that they are “natural” and perhaps
safer than prescription medications. In addition, patients
often do not perceive a need to seek the assistance of a
healthcare professional with these alternative therapies, and
they also may be an alternative to previously failed attempts
with conventional approaches [6].
Despite widespread use, there is still limited data on
the safety and eﬃcacy of the products currently on the
market. Because dietary supplements are viewed as food
and not drugs, they are not regulated by the Food and
Drug Administration (FDA). Instead, under the Dietary
Supplement Health and Education Act (DSHEA), dietary
supplements can be marketed without evidence to support
eﬃcacy and safety. If a dietary supplement appears to be2 Journal of Obesity
unsafe after being marketed, the FDA can then decide
whether or not to have the product removed from the
market. This was the case for the weight loss supplement
ephedra which was removed from the market in 2004 after
reports of serious health risks [5]. The literature published in
the arena of weight loss continues to be plagued by concerns
such as: small studies, inconsistency with participant body
weight (BMI), variation in length of studies, use of exercise,
a n dav a r i e t yo fp r o d u c t sa td i ﬀering dosages.
Several mechanisms are proposed to diﬀerentiate how
these products work. These include products that claim to
be: fat blockers, lipotropics or fat busters, thermogenic or
energymodiﬁers,andproductsthatcanchangecarbohydrate
metabolism, water elimination, or the feeling of satiety
or fullness. The purpose of this paper is to review the
literature on dietary supplements currently being marketed
and promoted for weight loss via the mechanisms of altered
fat absorption, fat metabolism and/or the storage of fat.
2. Methods
Published articles and abstracts were identiﬁed using
PubMed, MEDLINE, International Pharmaceutical Abstracts,
Cochrane Database, and Google Scholar with the search
termsdietarysupplement,herbal,weightloss,obesity,andby
using individual supplement names. The primary emphasis
was on pertinent articles based on human trials involving
overweight subjects that were performed in a randomized
and placebo-controlled process. Additional articles were
identiﬁed from the references of the retrieved literature.
Only studies that tested single dietary supplement products
were included in this paper. Studies which included multiple
products were not included due to inconclusive evidence of
the eﬀectiveness of individual products.
2.1. Fat Modifying Supplemental Weight Loss Products.
Table 1 summarizes the data for the following fat modifying
supplemental weight loss products.
2.1.1. Conjugated Linoleic Acid. Conjugated linoleic acid
(CLA) is a naturally occurring fatty acid that is found in
beef and dairy products [7]. Studies conducted in animals
have shown that CLA is eﬀective in reducing body fat mass,
increasing insulin sensitivity, decreasing plasma glucose
levels, is anticarcinogenic, and may have positive eﬀects
on atherosclerosis [8]. Conjugated linoleic acid has been
indicated for the use in cancer, diabetes, hypertension, and
h y p e r c h o l e s t e r o l e m i a ,a sw e l la sw e i g h tl o s sa n db o d yf a t
reduction. In regards to weight loss, CLA is believed to
workby promoting apoptosis in adipose tissue. Many animal
s t u d i e sh a v es h o w nC L At ob ee ﬀective in weight loss and
body fat reduction. This information has led to an increased
interestastowhetherornotCLAwouldhavethesameeﬀects
in humans [7].
Blankson et al. [9]p e r f o r m e dar a n d o m i z e d ,d o u b l e -
blind, placebo-controlled trial in which 52 patients (35
women and 17 men) with a BMI between 25 to 35kg/m2
were randomized to receive CLA 1.7, 3.4, 5.1, or 6.8 grams
per day or placebo (9 grams of olive oil) for 12 weeks. At
the end of 12 weeks, the results demonstrated a decrease
in body fat mass (BFM) of 1.73kg in the group receiving
CLA 3.4 grams (P ≤ .05) and a decrease of 1.3kg in the
groupreceiving6.8grams(P ≤ .05).Therewerenostatistical
diﬀerences seen in body mass, BMI, or lean body mass
(LBM). The most common adverse eﬀects reported were
gastrointestinal eﬀects [9].
In a double-blind, placebo-controlled study performed
by Ris´ erus et al. [10], 24 men with an average baseline BMI
of32kg/m2 wererandomizedtoreceiveeitherCLA4.2grams
p e rd a yo rp l a c e b of o r4w e e k s .A l o n gw i t ho t h e rw e i g h t
relatedendpoints,thisstudyalsoevaluatedtheeﬀectsofCLA
on sagittal abdominal diameter (SAD) as abdominal obesity
has been linked with the metabolic syndrome. At the end of
the study period, it was found that there was a signiﬁcant
decrease in SAD (−0.57cm, P = .04). However, there was no
diﬀerenceseeninbodyweightorBMI.Therewerenoadverse
events reported [10].
A randomized, double-blind, placebo-controlled study
by Smedman and Vessby [11] evaluated the eﬀects of CLA
4.2 grams per day versus placebo for 12 weeks on percent
body fat, body weight, BMI, and SAD in 50 patients (25 men
and25women)withanaverageBMIof25kg/m2.Theresults
showed a 3.8% decrease in body fat in those receiving CLA
(P = .05). There was no change seen in body weight, BMI,
and SAD. CLA was well tolerated by all participants [11].
C L Ai sm a r k e t e da se i t h e rat r i a c y l g l y c e r o lo rf r e ef a t t y
acid (FFA). Gaullier et al. [8] decided to not only evaluate
the eﬀectiveness of CLA on weight loss, but to see if either
CLA-triacylglycerol or CLA-FFA is more eﬃcacious than
the other. This was a double-blind, placebo-controlled trial
in which 180 patients (31 men and 149 women) with an
average BMI of 28kg/m2 were randomized to receive 4.5
grams of olive oil (placebo), 4.5 grams 80% CLA-FFA, or 4.5
grams 76% CLA-triacylglycerol for 12 months. The results
demonstratedasigniﬁcantdecreaseinBFMinboththeCLA-
FFA and CLA-triacylglycerol groups compared to placebo
(−1.7a n d−2.4, resp.; P<. 05). In the CLA-triacylglycerol
group, there was also a signiﬁcant decrease in body weight
(−1.8kgversus0.2kg;P<. 05) and BMI (−0.6kg/m 2 versus
1.8kg/m2; P<. 05) when compared with placebo. The CLA-
FFA group demonstrated an increase in LBM (2.0kg versus
0; P<. 05). All adverse events reported were rated as “mild”
or “moderate” with the most common being gastrointestinal
side eﬀects [8].
Of the 180 participants of this study, 134 continued
on in an open-label study for another 12 months. All
participants remained in their original treatment arm, but
all were treated with 4.5 grams daily of CLA-triacylglycerol
for the remaining 12 months. While there was no additional
decrease in body weight or BFM, this study did demonstrate
that participants were able to maintain their weight loss.
While two patients were observed to have an increase in
aspartate amino transferase (ASAT), these levels returned
to normal once CLA was discontinued (P = .002, CLA-
FFA; P = .009, CLA-triacylglycerol). Overall, this study
demonstrated that CLA use is safe over 24 months and
may be beneﬁcial in initial weight loss and may help withJournal of Obesity 3
Table 1: Summary data of fat modifying supplemental weight loss products.
Dietary
Supplement Trial Average BMI
(kg/m2) Treatment Length of
Treatment Results
Conjugated
linoleic acid
Blankson et al.
[9] 25–35 CLA 1.7, 3.4, 5.1, or 6.8
grams/day or placebo 12 weeks
↓ BFM with CLA 3.4 grams
(−1.73kg, P = .05) and 6.8 grams
(−1.3kg,P = .02).
No diﬀerences in body weight or
BMI
Ris´ erus et al.
[10] 32 CLA 4.2 grams/day or
placebo 4w e e k s
↓ SAD in CLA group (−0.57cm,
P = .04).
No diﬀerence in body weight or
BMI
Smedman and
Vessby [11] 25 CLA 4.2 grams/day or
placebo 12 weeks
↓ % body fat in CLA group (−3.8%,
P = .05).
No change in body weight or BMI
Gaullier et al.
[8] 28
4.5 grams/day of
CLA-FFA, 4.5 grams/day
of CLA-triacylglycerol,
or placebo
12 months
↓ BFM with CLA-triacylglycerol
and CLA-FFA groups (−1.7a n d
−2.4kg,resp.;P<. 05)
↓ Body weight with
CLA-triacylglycerol (−1.8kg,
P<. 05)
↓ BMI with CLA-triacylglycerol
(−0.6kg/m 2, P<. 05)
↑ LBM with CLA-FFA (2.0kg,
P<. 05)
Gaullier et al.
[12] 28
4.5 grams/day of
CLA-FFA, 4.5 grams/day
of CLA-triacylglycerol,
or placebo
24 months No additional ↓ body weight or
BFM
Garcinia
cambogia
(Hydroxycitric
acid)
Heymsﬁeld et al.
[13] 32
Garcinia cambogia
3000mg/day (1500mg
of HCA) or placebo
12 weeks
Both groups demonstrated weight
loss and decrease in percent body
fat; there was no diﬀerence between
the groups
Mattes and
Bormann [14] NR
Garcinia cambogia
2.4g/day (1.2g of HCA)
or placebo
↓ 3.7kg with Garcinia cambogia
versus ↓ 2.4kg with placebo
Chitosan
Pittler et al. [15]2 6 Chitosan 1 gram, or
placebo twice daily 28 days No diﬀerence between groups in
regards to body weight or BMI
Schiller et al.
[16] 32 Chitosan 1500mg or
placebo twice daily 8w e e k s
↓ Body weight of 1kg with chitosan
(P<. 005)
↓ BMI of 0.3kg/m2 with chitosan
(P<. 01)
↑Body weight of 1.5kg with placebo
(P<. 001)
↑ BMI of 0.6kg/m2 with placebo
(P<. 01)
Ni Mhurchu
et al. [17] 35–36 Chitosan 3 grams/day or
placebo 24 weeks
Chitosan group lost 0.39kg versus a
weight gain of 0.17kg in the
placebo group (P = .03)
Kaats et al. [18]N R
Chitosan 3 grams/day
with behavior
modiﬁcation; placebo
with behavior
modiﬁcation; or
minimal intervention
control
60 days
↓ Body weight of 2.8lbs. with
chitosan versus placebo (P = .03)
↓ Percent body fat of 0.8% with
chitosan versus placebo (P = .003)
↓ Fat mass of 2.6lbs. with chitosan
versus placebo (P = .001)
↑ BCI of 2.4lbs. with chitosan
versus placebo (P = .002)4 Journal of Obesity
Table 1: Continued.
Dietary
Supplement Trial Average BMI
(kg/m2) Treatment Length of
Treatment Results
Pyruvate
Stanko et al.
[19] 27.8–52.7
Pyruvate 30 grams/day
and calcium pyruvate 16
grams/day, or placebo
21 days
↓ 0.22kg with pyruvate versus
↓ 0.17kg with placebo (P<. 05)
↓ BMI 2.2kg/m2 with pyruvate
versus ↓ 1.5kg/m2 with placebo
(P<. 05)
↓ Fat 7.3% with pyruvate versus ↓
5.4% with placebo (P<. 05)
Kalman et al.
[20] >25
Pyruvate 6 grams/day,
placebo or nothing
(control)
6w e e k s
↑ LBM 2.4% with pyruvate
(P = .001)
↓ Fat mass 12.2% with pyruvate
(P<. 001), and
↓ Body fat 12.4% with pyruvate
(P<. 001)
Kalman et al.
[21] >25 Pyruvate 6 grams/day, or
placebo 6w e e k s
↓ Body weight 1.6% with pyruvate
(P<. 001)
↓ Body fat 14% with pyruvate
(P<. 001)
↓ % body fat 11.7% with pyruvate
(P<. 001)
Irvingia
gabonensis
Ngondi et al.
[22] NR Irvingia gabonensis
350mg/day, or placebo 4w e e k s
↓ Body weight 5.6% with Irvingia
gabonensis (P<. 0001)
↓ Waist circumference 5.07% with
Irvingia gabonensis (P<. 0001)
↓ Hip circumference 3.42% with
Irvingia gabonensis (P<. 0001)
Ngondi et al.
[23] 26–40 Irvingia gabonensis
150mg/day, or placebo 10 weeks
↓ Body weight 12.8kg with Irvingia
gabonensis (P<. 01)
↓ Waist circumference 16.19cm
with Irvingia gabonensis (P<. 01)
↓ % body fat 6.3% with Irvingia
gabonensis (P<. 05)
Chia seeds
(Salvia
hispanica)
Nieman et al.
[24] NR Chia seeds 50g/day, or
placebo 12 weeks No diﬀerences in body mass or
body composition
BCI: Body Composition Improvement, BFM: Body Fat Mass, BMI: Body Mass Index, CLA: Conjugated Linoleic Acid, FFA: Free Fatty Acid, HCA:
Hydroxycitric Acid, LBM: Lean Body Mass, NR: Not Reported, SAD: Sagittal Abdominal Diameter.
maintaining weight loss and reductions in BFM. The most
commons adverse events reported were gastrointestinal [12].
Studies reviewed indicate that CLA appears to be safe
with the most common adverse eﬀects being gastrointestinal
(GI). Overall, it appears as though that CLA helps to reduce
BFM and SAD in patients, but minimal eﬀect on BMI or
body weight. In addition, CLA may be beneﬁcial in helping
to maintain changes in body composition such as reductions
in BFM.
2.1.2. Garcinia cambogia (Hydroxycitric Acid). Hydroxycitric
acid (HCA) is the active ingredient found in the fruit
of the Garcinia cambogia plant [25]. It is believed that
hydroxycitric acid aids in weight loss by inhibiting lipogen-
esis by inhibiting the adenosine triphosphate (ATP)-citrate-
lyase enzyme which is responsible for converting citrate to
acetyl-coenzyme A and ultimately fatty acid synthesis. It is
also theorized that HCA may improve exercise endurance
by increasing lipid oxidation and decreasing carbohydrate
metabolism and stimulate appetite suppression [13, 25].
Heymsﬁeld et al. [13] performed a randomized, double-
blind, placebo-controlled trial to measure the eﬀects of HCA
on body weight change and fat mass. The 135 participants
(19 men and 116 women) with an average BMI of 32kg/m2
were randomized to receive 3000mg of Garcinia cambogia
(1500mgofHCA)perdayorplaceboalongwithahighﬁber,
low-calorie diet for 12 weeks. The placebo group lost 4.1kg,
and the HCA group lost 3.2kg. While the results within
each separate treatment arm was signiﬁcant when compared
to baseline, there were no diﬀerences between the groups
(P = .14). In addition, the placebo group demonstrated a
decrease in percent body fat mass of 2.16%, and the HCA
group demonstrated a 1.44% decrease. Again, there were
no diﬀerences between the groups (P = .08). The most
commonly reported adverse events were headache, upper
respiratory tract symptoms, and gastrointestinal symptoms.Journal of Obesity 5
However, there were no diﬀerences between the HCA group
and placebo [13].
A double-blind, placebo-controlled parallel group study
performed by Mattes and Bormann [14] enrolled 89 mildly
overweight females to evaluate HCA on weight loss and
appetite suppression. The participants were randomized to
receive 2.4 grams of Garcinia cambogia (1.2 grams of HCA)
or placebo per day, in addition to a low calorie diet. At
the end of 12 weeks, it was noted that the HCA group lost
signiﬁcantlymoreweightthantheplacebogroup(3.7±3.1kg
versus 2.4 ± 2.9kg). There were no changes on appetitive
variables [14, 26].
While HCA appears to be well tolerated, there is limited
data with regards to its eﬃcacy. The data that is available,
however, does not demonstrate signiﬁcant weight loss.
Therefore, Garcinia cambogia o rH C Ai sn o tr e c o m m e n d e d
at this time.
2.1.3. Chitosan. Chitosan is a form of chitin that comes
from the shells of crustaceans such as shrimp, lobster, and
crab. Several in vitro studies have shown that chitosan
binds dietary fats and bile acids. Because of this proposed
mechanism of action, it is theorized that chitosan may be
u s e f u lf o rw e i g h tc o n t r o l ,a sw e l la sf o rat r e a t m e n to f
hypercholesterolemia [15–18, 27, 28].
A randomized, double-blind placebo-controlled trial
performed by Pittler et al. [15] examined the eﬀects of
chitosan on weight loss. Thirty-four patients (6 men and
28 women) with a BMI of approximately 26kg/m2 were
randomized to receive one gram chitosan or placebo twice
daily for 28 days. At the end of the study period, there was no
diﬀerence in body weight or BMI between the two groups.
Adverse eﬀects reported with chitosan were minor. The most
common complaint was constipation [15].
Schiller et al. [16] evaluated the use of rapidly soluble
chitosan in weight loss and reducing body fat in 59 partic-
ipants with an average BMI of 32kg/m2 consuming a high
fat diet. In this double-blind, placebo-controlled trial, the
participants were randomized to receive 1500mg of chitosan
or placebo twice a day with the largest meals of the day
for eight weeks. At the end of the study period, patients
in the chitosan group lost 1kg (P<. 005), and the BMI
was signiﬁcantly decreased by 0.3kg/m2 (P<. 01). Patients
in the placebo group gained 1.5kg (P<. 001), and the
BMI was signiﬁcantly higher by 0.6kg/m2 (P<. 01). When
treatment was compared to placebo, weight and BMI were
signiﬁcantly higher in the placebo group (P<. 0001 and
P<. 05, resp.). The most common adverse eﬀects reported
were gastrointestinal, ﬂatulence, increased stool bulkiness,
bloating, nausea, and heartburn. This study demonstrated
that chitosan may be an eﬀective weight loss supplement
[16].
Ni Mhurchu et al. [17] evaluated the eﬀects of chitosan
on 250 patients (44 men and 206 women) with a BMI
35 to 36kg/m2. This double-blind, placebo-controlled trial
randomized patients to receive three grams of chitosan per
day or placebo in addition to receiving standardized dietary
and lifestyle advice. The trial was conducted over 24 weeks.
At the end of the study period, the chitosan group lost more
weight than placebo (−0.39 versus +0.17kg, P = .03). There
were ten serious adverse events, four of which occurred in
the chitosan group. These included three hospitalizations
and one cancer incidence. Thirty-six participants in the
chitosan group reported some minor adverse events which
were primarily gastrointestinal related [17].
In a randomized, double-blind, placebo-controlled trial
by Kaats et al. [18], 150 overweight adults were randomized
to three study groups: three grams of chitosan per day and
a behavior modiﬁcation program, placebo and a behavior
modiﬁcation program, or a minimum intervention control
group. The trial was conducted over 60 days. At the end
of the study period, participants in the chitosan group
demonstrated a signiﬁcant reduction in weight compared to
control (−2.8v e r s u s+ 0 .8 pounds, P<. 001) and a decrease
in fat mass compared to control (P = .006). When compared
to placebo, the chitosan group demonstrated a decrease in
weight (−2.8v e r s u s−0.6 pounds, P = .03), a decrease in
percent fat (−.08% versus +0.4%, P = .003), a decrease in fat
mass (−2.6v e r s u s+ 0 .6 pounds, P = .001), and an increase
in body composition improvement (BCI) (+2.4 versus −1.9
pounds, P = .002) [18].
Chitosaniswelltoleratedwiththemostcommonadverse
eﬀects being gastrointestinal. Based on the above studies,
it appears as though chitosan may be eﬀective to help aid
weight loss. Because of limited data thus far, chitosan cannot
be recommended at this time. Chitosan, however should be
avoided in individuals with a shellﬁsh allergy [27].
2.1.4. Pyruvate. Pyruvate is a three-carbon compound that
is a byproduct of glucose metabolism. It is unclear how
pyruvate works to promote weight loss, but in rats a lower
respiratory exchange ratio has been demonstrated indicating
that there was increased utilization of fat and an elevation in
resting metabolic rate [21, 29].
Stanko et al. and Kalman et al. both performed several
studies evaluating the use of pyruvate in weight loss [19–21].
The study performed by Stanko et al. [19]w a sad o u b l e -
blind, placebo-controlled trial which evaluated body com-
position with a low energy diet and supplementation with
pyruvate. Fourteen women with a BMI 27.8 to 52.7kg/m2
wereplacedonalowenergydietandthenrandomlyassigned
t or e c e i v ee i t h e r3 0g r a m so fp y r u v a t ep l u s1 6g r a m so f
calcium pyruvate per day or placebo for 21 days. The
pyruvate group lost 0.22kg compared to 0.17kg in the
placebogroup(P<. 05),andtherewasalsoadecreaseinBMI
of 2.2kg/m2 compared to 1.5kg/m2 in the placebo group
(P<. 05).Inaddition,thepyruvategrouplost7.3%fatversus
5.4% in the placebo group (P<. 05) [19].
In the ﬁrst study by Kalman et al. [20] a randomized,
double-masked, placebo-controlled trial was performed in
which participants received six grams/day of pyruvate,
placebo, or nothing (control group) along with diet and
exercisecounseling.The51participants(25men,26women)
enrolled had a BMI greater than 25kg/m2. At the end of six
weeks, fat mass decreased signiﬁcantly (−12.2%; P<. 001),
percent body fat decreased signiﬁcantly (−12.4%; P<. 001),
and lean body mass increased (+2.4%; P = .001) in the
pyruvategroupwhencomparedtobaseline.Theplaceboand6 Journal of Obesity
control groups did not demonstrate any signiﬁcant changes
in fat mass, percent body mass, and lean body mass [20].
Kalman et al. [21] performed another six week, double-
blind, placebo-controlled trial. Twenty-six subjects (10 men,
16women)withaBMIgreaterthan25kg/m2 were randomly
assigned to receive six grams of pyruvate per day or placebo.
At the end of the trial, there was a 1.6% decrease in body
weight (P<. 001), a 14% decrease in body fat (P<. 001),
and an 11.7% decrease in percent body fat (P<. 001) in
the pyruvate group. There were no signiﬁcant changes in the
placebo group [21].
In studies published thus far, pyruvate has demonstrated
that it may be beneﬁcial for weight loss. In addition, it
tends to be well tolerated with minimal adverse eﬀects. The
most common adverse eﬀect is gastrointestinal upset [29].
However, the trials conducted so far have had small sample
sizesandhaveonlybeenperformedforshortperiodsoftime.
Although it appears to be safe, there is no data on the long
term use of pyruvate.
2.1.5. Irvingia Gabonensis. Irvingia gabonensis is a mango-
like fruit that comes from the deciduous forest tree found
in West Africa [22, 30]. It is theorized that Irvingia gabo-
nensis works by inhibiting adipogenesis by down-regulating
peroxisome proliferator-activated receptor gamma (PPAR-
gamma) which is responsible for the diﬀerentiation of
adipocytes. In addition, it also observed that adiponectin
levels increase and leptin levels decrease in patients given
Irvingia gabonensis. Irvingia gabonensis has also been used to
treat hypercholesterolemia [30].
The ﬁrst trial was performed by Ngondi et al. in 2005.
This was a randomized, double-blind, placebo-controlled
trial that enrolled 40 obese subjects in Cameroon. Subjects
were randomly assigned to receive 350mg of Irvingia
gabonensis seed extract or placebo for 4 weeks. At the end
of the 4 weeks, the Irvingia gabonensis group was observed
t oh a v ead e c r e a s ei nb o d yw e i g h to f5 .6 ± 2.7% (P<
.0001), a decrease in waist circumference of 5.07 ± 3.18%
(P<. 0001), and a decrease in hip circumference of 3.42 ±
2.12% (P<. 0001). The placebo group observed a decrease
in body weight of 1.32 ± 0.41%. There was no change in
percent body fat for both the treatment and placebo groups
[22].
A second article by Ngondi et al. [23] also examined
the eﬀects of Irvingia gabonensis on weight loss. This was a
double-blind, placebo-controlled trial in which 102 natives
of Cameroon with a BMI of 26 to 40kg/m2 were randomized
to receive 150mg of Irvingia gabonensis or placebo daily
for ten weeks. At the end of the study period, there was
a signiﬁcant diﬀerence between the treatment group and
placebo for body weight (−12.8kgversus−0.7kg;P<. 01),
waist circumference (−16.19cm versus −5.3cm;P<. 01),
and percent body fat (−6.3% versus −1.99%; P<. 05) [23].
Although the current data looks encouraging, to date
there is limited data on the use if Irvingia gabonensis in
weight loss. It appears to be safe and well tolerated as the
most common adverse eﬀects are headache, ﬂatulence, and
diﬃculty sleeping [30]. Due to the limited data, Irvingia
gabonensis cannot be recommended at this time.
2.1.6. Chia Seed (Salvia hispanica). Chia seed, or Salvia
hispanica, is a sprout that has high concentrations of omega-
3-fatty acids, alpha-linoleic acid, and ﬁber [24, 31]. It has
been hypothesized that these components of the seeds would
not only help with diseases such as hypercholesterolemia or
diabetes, but that it may also be beneﬁcial in weight loss.
Nieman et al. [24] performed a single-blinded, trial in which
76overweight/obeseparticipantswererandomizedtoreceive
50gramsofchiaseeddailyorplacebo.Attheendof12weeks,
itwasnotedthattherewerediﬀerencespre-andpoststudyon
body mass or body composition [24]. While considered safe
in the short term, there is limited data to suggest the use of
chia seeds for weight loss.
3. Conclusion
Because the prevalence of obesity in the United States is
signiﬁcant, many people turn to the use of supplemental
products as an assist with weight loss eﬀorts. While there
areseveraldietarysupplementsbeingmarketedfortheusein
weight loss via several diﬀerent mechanisms of action, there
isverylittleclinicalevidencetosupporttheiruse.Conjugated
linoleic acid, pyruvate, and Irvingia gabonensis have shown
some potential beneﬁt for weight loss. However, more data
is necessary to draw any deﬁnitive conclusions on the use of
dietary supplements for weight loss. Continued research is
needed in this area to aid health care providers as well as the
public in general. Health care providers should be aware of
the weight loss products available to their patients and assist
patients in determining the risks and beneﬁts of supplement
use for weight loss.
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